Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats
The DOI matches its Crossref record; 51 of the 57 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that is secreted during meal absorption and is essential for normal glucose homeostasis. However, the relatively low plasma levels and rapid metabolism of GLP-1 raise questions as to whether direct endocrine action on target organs, such as islet cells, account for all of its effects on glucose tolerance. Recently, an alternative neural pathway initiated by sensors in the hepatic portal region has been proposed to mediate GLP-1 activity. We hypothesized that visceral afferent neurons in the portal bed express the GLP-1 receptor (GLP-1r) and regulate glucose tolerance. Consistent with this hypothesis, GLP-1r mRNA was present in the nodose ganglia, and nerve terminals innervating the portal vein contained the GLP-1r. Rats given an intraportal infusion of the GLP-1r antagonist, [des-His(1),Glu(9)] exendin-4, in a low dose, had glucose intolerance, with a 53% higher glucose excursion compared with a vehicle-infused control group. Infusion of [des-His(1),Glu(9)] exendin-4 at an identical rate into the jugular vein had no effect on glucose tolerance, demonstrating that this dose of GLP-1r antagonist did not affect blood glucose due to spillover into the systemic circulation. These studies demonstrate that GLP-1r are present on nerve terminals in the hepatic portal bed and that GLP-1 antagonism localized to this region impairs glucose tolerance. These data are consistent with an important component of neural mediation of GLP-1 action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 receptor was found in nerves that innervate hepatocytes [172], but their presence on human liver or hepatocytes is debated as found by some [169,170] but not others [173,174].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [172]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Cited by
Items 201–300 of 315
Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Moreno, P., Nuche‐Berenguer, B., Gutiérrez-Rojas, I., Acitores, A., Sancho, V., Valverde, I., González, N., & Villanueva‐Peñacarrillo, M. L. (2011) · Journal of Molecular Endocrinology · doi:10.1530/jme-11-0127 · Cited by 28
“Evidences from a report (Valh et al. 2007) demonstrating the presence of GLP-1 receptor in the terminal nerves of the portal vein should be taken into account; although the first step in the action of Ex-4 in the liver remains unknown, because of its homology with GLP-1, the possibility that its effects could be media…”
BackgroundGLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 25
“109 When this is combined with low ‐ dose portal vein infusion of a GLP ‐ 1r antagonist, an increase in glucose levels of 53% is seen.”
BackgroundGlucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
HOFFMAN, S. S., & Adeli, K. (2024) · Medical Review · doi:10.1515/mr-2024-0011 · Cited by 26
“Similarly, portal vein infusion of exendin 9 – 39 in rats has been shown to worsen glucose tolerance [41].”
BackgroundThe Anorectic Effect of GLP-1 in Rats Is Nutrient Dependent
Sandoval, D., Barrera, J. G., Stefater, M. A., Sisley, S., Woods, S. C., D’Alessio, D. D., & Seeley, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051870 · Cited by 22
“To determine if glucokinase, an important neuronal glucose sensor [34], is a mediator of GLP-1 action, we administered IP GLP-1 plus vildagliptin, or IP exendin-4, a longacting GLP-1 agonist, to GK-heterozygote knockout and littermate control mice.”
MethodSelf-citationInfluence of gastrointestinal factors on glucose metabolism in patients with cirrhosis
Junker, A. E., Gluud, L. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12981 · Cited by 21
RISING STARS: Endocrine regulation of metabolic homeostasis via the intestine and gut microbiome
Meyer, R. K., & Duca, F. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0019 · Cited by 28
García-Luna, C., Sanchez‐Watts, G., Arnold, M., de Lartigue, G., DeWalt, N., Langhans, W., & Watts, A. G. (2021) · eNeuro · doi:10.1523/eneuro.0419-20.2021 · Cited by 23
“, 2012), amino acids (Niijima and Meguid, 1995), and the hormones glucagon (Geary, 1990), GLP-1 (Nakabayashi et al., 1996; Balkan and Li, 2000; Vahl et al., 2007), leptin (Shiraishi et al.”
InfluentialNonogaki, K., Suzuki, M., Sanuki, M., Wakameda, M., & Tamari, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.175 · Cited by 21
Nutrient control of hunger by extrinsic gastrointestinal neurons
Mithieux, G. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.04.005 · Cited by 26
Nutrient Control of Energy Homeostasis via Gut-Brain Neural Circuits
Mithieux, G. (2014) · Neuroendocrinology · doi:10.1159/000369070 · Cited by 24
Is the GLP-1 system a viable therapeutic target for weight reduction?
Tong, J., & Sandoval, D. A. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9170-8 · Cited by 23
“However, GLP-1 action in the portal vein seems to be more important for glucose homeostasis [78] rather than food intake [79].”
BackgroundWei, H., Wu, H., Fan, H. J., Li, T., Ma, A., Li, X., Wang, Y., & Pertovaara, A. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.11.008 · Cited by 19
“The sequences of primers were following: DAAO: 50-CCC TTT CTG GAA AAG CAC AG30 (forward), 50-CTC CTC TCA CCA CCT CTT CG-30 (reverse) [13]; TRPA 1: 50-CTC AGG TTC AAT GTG TCC GTTC-30 (forward), 50-GTG CTG TGT TCC CTT CTT CATC-30 (reverse) [14]; GAPDH: 50-CCA AGG TCA TCCATG ACA AC-30 (forward), 50-TCC ACA GTC TTC TGA GT…”
Yang, J., Sun, Y., Xu, F., Liu, W., Mai, Y., Hayashi, T., Hattori, S., Ushiki‐Kaku, Y., Onodera, S., Tashiro, S., et al. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3414-9 · Cited by 21
Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats
Aulinger, B. A., Perabò, M., Seeley, R. J., Parhofer, K. G., & D’Alessio, D. A. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00298.2019 · Cited by 21
Self-citationMalbert, C.-H., Chauvin, A., Horowitz, M., & Jones, K. L. (2021) · Diabetes · doi:10.2337/db20-0361 · Cited by 18
Eldor, R., Kidron, M., Greenberg-Shushlav, Y., & Arbit, E. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400629 · Cited by 19
Williams, K. E., Washington, M. C., Johnson-Rouse, T., Johnson, R. E., Freeman, C., Reed, C., Heath, J. C., & Sayegh, A. I. (2015) · Appetite · doi:10.1016/j.appet.2015.09.030 · Cited by 18
“(6) In rats, vagal afferents supplying the GI tract express GLP-1R (Bucinskaite et al., 2009; Nakagawa et al., 2004; Vahl et al., 2007).”
BackgroundHepatic interoception in health and disease
Berthoud, H., Münzberg, H., Morrison, C. D., & Neuhuber, W. (2024) · Autonomic Neuroscience · doi:10.1016/j.autneu.2024.103174 · Cited by 19
“Using double-IHC it was later demonstrated that synaptophysin-positive nerve fibers of unknown origin in the wall of the rat portal vein co-express GLP1R, and that GLP1R is expressed in a population of vagal afferent neurons in the nodose ganglia (Vahl et al., 2007).”
Ahrén, B., Yamada, Y., & Seino, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.665537 · Cited by 15
“In contrast, the GLP-1 receptor KO mice had higher AUCglucose than the other groups after 25 and 50 mg, but this was mainly related to the higher fasting glucose, which most likely is a phenomenon explained by exaggerated hepatic glucose production due to absence of GLP-1 action to inhibit liver glucose production, wh…”
BackgroundGlucose Sensing in the Hepatic Portal Vein and Its Role in Food Intake and Reward
Bacharach, S. Z., Tordoff, M. G., & Alhadeff, A. L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.012 · Cited by 17
Tough, I. R., Moodaley, R., & Cox, H. M. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13149 · Cited by 17
Ionut, V., Castro, A. V. B., Woolcott, O. O., Stefanovski, D., Iyer, M. S., Broussard, J. L., Burch, M., Elazary, R., Kolka, C. M., Mkrtchyan, H., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2014 · Cited by 13
Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes
Ahrén, B. (2015) · Diabetes · doi:10.2337/db14-1671 · Cited by 13
“glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.”
BackgroundResultAndo, H., Gotoh, K., Fujiwara, K., Anai, M., Chiba, S., Masaki, T., Kakuma, T., & Shibata, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-05371-4 · Cited by 14
Guldstrand, M., Åhrén, B., Näslund, E. B., Holst, J. J., & Adamson, U. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01089.x · Cited by 13
Updating the Role of α-Cell Preproglucagon products on GLP-1 receptor–mediated insulin secretion
Sandoval, D. (2020) · Diabetes · doi:10.2337/dbi19-0027 · Cited by 12
Psychotropic effects of GLP-1R agonists
Bucciarelli, L. G., Cimino, V., Dell’Osso, B. M., & Fiorina, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108036 · Cited by 19
Rezaie, P., Bitarafan, V., Rose, B. D., Lange, K. M., Mohammadpour, Z., Rehfeld, J. F., Horowitz, M., & Feinle‐Bisset, C. (2023) · Nutrients · doi:10.3390/nu15163584 · Cited by 13
“In females, the 600 mg dose of quinine abolished the rise in plasma glucose after the drink, which likely reflects the interplay between a number of factors, including the slowing of gastric emptying, mediated, in part, by GLP-1 and CCK [36,37] and, potentially, the direct effect of quinine on gut smooth muscle cells…”
BackgroundCrosstalk between gastrointestinal neurons and the brain in the control of food intake
Mithieux, G. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.03.004 · Cited by 15
Therapeutic potential of spinal GLP-1 receptor signaling
Zhang, D., & Lv, G. (2018) · Peptides · doi:10.1016/j.peptides.2018.01.003 · Cited by 13
“[27] examined the mRNA expression of GLP-1R in several tissues via RT-PCR.”
Effect of portal glucose sensing on incretin hormone secretion in a canine model
Edgerton, D. S., Kraft, G., Smith, M. S., Moore, L. M., Farmer, B., Scott, M. F., Moore, M. C., Nauck, M. A., & Cherrington, A. D. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2019 · Cited by 12
Heap, A. J., & Cummings, D. E. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9514-y · Cited by 12
“The effects of GLP-1 on glucose homeostasis are largely dependent on signaling via the vagus nerve [ 29 ]; thus, increased GLP-1 secretion from L-cells after our operation should exert more potent anti-diabetic effects than would result from an equivalent increase in circulating GLP-1 signal strength following systemi…”
Backgroundde Sousa, É., Sparks, L. M., & Townsend, K. L. (2025) · Diabetes · doi:10.2337/db25-0158 · Cited by 13
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“Vahl et al. (2007) demonstrated that a low dose intraportal infusion of the GLP1R antagonist exendin (9–39) (Ex-9) caused glucose intolerance.”
InfluentialWei, H., Wu, H., Chen, Z., Ma, A., Mao, X.-F., Li, T., Li, X., Wang, Y., & Pertovaara, A. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.09.007 · Cited by 11
“…5′-CTC CTC TCA CCA CCT CTT CG3′(reverse) (Zhao et al., 2010); TRPA 1: 5′-CTC AGG TTC AAT GTG TCC GTTC-3′(forward), 5′-GTG CTG TGT TCC CTT CATC-3′(reverse) (Du et al., 2007); GAPDH: 5′-CCA AGG TCA TCCATG ACA AC-3′ (forward), 5′- TCC ACA GTC TTC TGA GTGGC-3′ (reverse) (Vahl et al., 2007).”
BackgroundLiraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
Hansen, C. S., Frandsen, C. S., Fleischer, J., Vistisen, D., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., Andersen, H. U., & Dejgaard, T. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00242 · Cited by 11
“Activation of GLP1 receptors in peripheral vagal neurons (6, 7) seems to be involved, suggesting that dysfunction of the vagal nerve may affect the body weight-reducing effect of liraglutide in patients.”
BackgroundNakajima, S., Numakawa, T., Adachi, N., Yoon, H. S., Odaka, H., Ooshima, Y., & Kunugi, H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.052 · Cited by 12
Repurposing GLP1 agonists for neurodegenerative diseases
Markaki, I., Winther, K., Catrina, S., & Svenningsson, P. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.02.007 · Cited by 14
Accentuated early postprandial satiety in people with spinal cord injury versus able-bodied controls
Fenton, J. M., King, J. A., Hoekstra, S. P., Willis, S. A., Ogawa, T., & Goosey-Tolfrey, V. L. (2021) · Appetite · doi:10.1016/j.appet.2021.105628 · Cited by 11
Exenatide and feeding: Possible peripheral neuronal pathways
Hunt, J. V., Washington, M. C., & Sayegh, A. I. (2011) · Peptides · doi:10.1016/j.peptides.2011.12.009 · Cited by 12
GLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 14
“GLP-1Rs are highly expressed in nodose ganglion neurons and on vagal afferent terminals innervating the gastrointestinal tract (Nakagawa et al. 2004; Vahl et al. 2007; Bucinskaite et al. 2009), and vagal signaling is well established to regulate metabolic homeostasis as well as the anorectic and…”
Kamemoto, K., Tataka, Y., Hiratsu, A., Nagayama, C., Hamada, Y., Kurata, K., Chiyoda, M., Ito, M., & Miyashita, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-58103-w · Cited by 12
“GLP-1 inhibits hepatic gluconeogenesis in the liver through activation of GLP-1 receptor on the vagal afferents innervating the hepatic portal vein 25 .”
BackgroundEvidence for neural contribution to islet effects of DPP-4 inhibition in mice
Ahlkvist, L., Omar, B. A., Pacini, G., & Åhrén, B. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.030 · Cited by 8
McVeay, C., Fitzgerald, P. C. E., Horowitz, M., & Feinle‐Bisset, C. (2019) · Nutrients · doi:10.3390/nu11112697 · Cited by 9
“Accordingly, blood glucose lowering may reflect the stimulation of GLP-1 receptors on portal vagal afferents [15], to enhance hepatic and peripheral glucose uptake [16].”
BackgroundPrediabetes blunts DPP4 genetic control of postprandial glycaemia and insulin secretion
Patarrão, R. S., Duarte, N., Coelho, I., Ward, J., Ribeiro, R. T., Meneses, M. J., Andrade, R., Costa, J., Correia, I., Boavida, J. M., et al. (2022) · Diabetologia · doi:10.1007/s00125-021-05638-6 · Cited by 11
“Several studies have suggested an alternative model of post-OGTT GLP-1 action through a neural circuit originating in the hepatic portal area [40].”
BackgroundSalehi, M., Peterson, R., Tripathy, D., Pezzica, S., DeFronzo, R. A., & Gastaldelli, A. (2023) · Obesity · doi:10.1002/oby.23872 · Cited by 11
“Another possibility is that greater β -cell effect of enhanced GLP-1 is mediated by nervous system activity, mainly vagal [ 44].”
BackgroundSchwartz, A., Ort, T., Kajekar, R., Wade, P. R., & Hornby, P. J. (2010) · Physiological Measurement · doi:10.1088/0967-3334/31/9/006 · Cited by 8
Simonsen, L., Pilgaard, S., Ørskov, C., Hartmann, B., Holst, J. J., & Deacon, C. F. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01066.x · Cited by 9
Portal milieu and the interplay of multiple antidiabetic effects after gastric bypass surgery
Pal, A., Rhoads, D. B., & Tavakkoli, A. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00389.2018 · Cited by 10
“Portal GLP-1 is detected by a portal GLP-1 sensor to improve glucose tolerance (38).”
BackgroundA role for PYY3-36 in GLP1-induced insulin secretion
Gautier‐Stein, A., & Mithieux, G. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.06.002 · Cited by 7
“For example, does PYY3-36 act directly on Y2R present in intestinal L-cells to induce and/or improve GLP-1 secretion? Does PYY3-36 act on Y2R via the autonomous nervous system, which is very dense within the walls of the portal vein [7], to stimulate GLP-1 secretion? Is there a role in this chain of the central nervou…”
BackgroundThe metabolic actions of neurotensin secreted from the gut
Ratner, C., Hundahl, C., & Holst, B. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000085 · Cited by 7
Special Features: Incretin-based therapies in type 2 diabetes mellitus
Cw, C., Jm, E., Chia, C. W., Egan, J. M., correspondence, A., & Egan, J. M. (2014) · Cited by 6
Post ingestive systemic nutrient sensing for whole-body homeostasis
Lee, G., Lee, J., Suh, G. S. B., & Oh, Y. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100271 · Cited by 8
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
GLP-1 expression in von Ebner's gland of diabetic rats
Feng, X., Zhou, L., Wang, D., & Yuan, X. (2012) · Peptides · doi:10.1016/j.peptides.2012.09.002 · Cited by 7
Åhrén, B. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.09.003 · Cited by 6
“Furthermore, the portal infusion of a GLP-1 receptor antagonist has been shown to induce glucose intolerance in rats [23].”
BackgroundVeedfald, S., Hansen, M., Christensen, L. W., Larsen, S. A. H., Hjøllund, K. R., Plamboeck, A., Hartmann, B., Deacon, C. F., & Holst, J. J. (2016) · Experimental Physiology · doi:10.1113/ep085692 · Cited by 6
“Glucagon-like peptide-1 receptor mRNA has been identified in nodose ganglion neurons (Nakagawa et al. 2004; Vahl et al. 2007) and nerve terminals in the hepatic portal vein (Vahl et al.”
BackgroundInfluentialRidge, T. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000114 · Cited by 6
“In addition to the neural effects, the acute effect of GLP-1 on glucose homeostasis is mediated by an endocrine pathway (Hansen, Deacon, Orskov, & Holst, 1999; Vahl et al., 2007).”
BackgroundG Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children
Dallatana, A., Cremonesi, L., Trombetta, M., Fracasso, G., Nocini, R., Giacomello, L., & Innamorati, G. (2023) · Biomedicines · doi:10.3390/biomedicines11061576 · Cited by 7
Gautier‐Stein, A., Vily‐Petit, J., Rajas, F., & Mithieux, G. (2023) · Biochimie · doi:10.1016/j.biochi.2023.11.012 · Cited by 5
Nonogaki, K., & Suzuki, M. (2013) · ISRN Endocrinology · doi:10.1155/2013/184753 · Cited by 7
“The afferent vagal nerve enters the NST, which projects into hypothalamic structures that are involved in appetite regulation [17, 18].”
BackgroundNovel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Zhou, M., Du, M., Tang, R., Liu, H., Gao, Z., Wang, Y., You, H., Hao, J.-W., Ji, Z., Wang, D., et al. (2023) · Neuroendocrinology · doi:10.1159/000529438 · Cited by 5
Trung, V. N., Yamamoto, H., Yamaguchi, T., Murata, S., Aimi, Y., Kuwahara, A., & Tani, T. (2013) · Peptides · doi:10.1016/j.peptides.2013.12.003 · Cited by 4
De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
Phan, F., Bertrand, R., Amouyal, C., & Andréelli, F. (2024) · médecine/sciences · doi:10.1051/medsci/2024153 · Cited by 4
Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
Bobok, N. M. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.3.2025.1544 · Cited by 4
Burcelin, R., & Bertolini, M. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70590-x · Cited by 5
Gilijamse, P. W., Demirkıran, A., van Wagensveld, B. A., Ackermans, M. T., Romijn, J. A., Nieuwdorp, M., ter Horst, K. W., & Serlie, M. J. M. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.04.022 · Cited by 5
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3
The Role of Adipose Tissue Vasculature in Energy Balance
Kim, H.-J., Choi, S.-H., Chun, B., & Kim, D.-H. (2011) · Journal of Korean Society of Pediatric Endocrinology · doi:10.6065/jkspe.2011.16.3.139 · Cited by 3
Salehi, M., Peterson, R., Tripathy, D., Pezzica, S., DeFronzo, R. A., & Gastaldelli, A. (2023) · medRxiv · doi:10.1101/2023.03.28.23287755 · Cited by 3
G LP ‐1 enhances β‐cell response to protein ingestion and bariatric surgery amplifies it
Rayas, M. S., Pezzica, S., Honka, H., Carli, F., Peterson, R. E., DeFronzo, R. A., Gastaldelli, A., & Salehi, M. (2024) · Obesity · doi:10.1002/oby.24182 · Cited by 4
“Although the translational significance of these findings in humans is difficult to establish, it has also been well recognized that GLP-1 signaling is detected by visceral afferent nerves in the hepatic portal region [35] or directly in the central nervous system [34, 36].”
Bashaw, A. G., Roman-Ortiz, C., Gao, S. X., Schier, L. A., Borner, T., & Kanoski, S. E. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.006 · Cited by 5
Mithieux, G. (2015) · Biologie Aujourd hui · doi:10.1051/jbio/2016001 · Cited by 3
Nutropioids Regulate Gut-Brain Circuitry Controlling Food Intake
Mithieux, G. (2014) · Frontiers of hormone research · doi:10.1159/000358344 · Cited by 3
Deacon, C. F. (2012) · Diabetes · doi:10.2337/db12-0649 · Cited by 2
“endin(9-39)amide as a GLP-1 receptor antagonist in humans (Abstract).”
BackgroundUsing the cerebrospinal fluid to understand ingestive behavior
Woods, S. C., May-Zhang, A. A., Liu, M., Tso, P., & Begg, D. P. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.11.037 · Cited by 2
“lumen, and it is thought to act on local sensory nerve endings [38] and also to enter the hepatic portal circulation, where before entering the general circulation, it stimulates GLP-1 receptors on afferent vagal branches located in the wall of the hepatic portal vein [39].”
BackgroundSelf-citationYamashita, S., Kawakami, Y., Satō, H., Sugitani, S., Goto, M., & Kato, N. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172521 · Cited by 2
Bedeutung von GLP‐1 für die Glucose‐Homöostase. Entdeckung der Inkretine
Blume, H. H., Wedemeyer, R., & Gallwitz, B. (2010) · Pharmazie in unserer Zeit · doi:10.1002/pauz.201000356 · Cited by 1
Fujishima, Y., & Maeda, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00015-5 · Cited by 1
Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog
Edgerton, D. S., An, Z., Johnson, K., Farmer, T. E., Farmer, B., Neal, D. W., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00160.2013 · Cited by 2
The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
Barrera, J. G. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Colonic delivery of nutrients for management of blood glucose in type 2 diabetes patients
Szewczyk, J. R., Giannone, J., Marcuard, S. P., Kindel, T. L., Tso, P., & Nolan, R. D. (2017) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v7i1.283 · Cited by 2
“The intestinal mucosa and hepatic portal vein are densely innervated with afferent nerves that respond to gut hormones [37; 38].”
BackgroundAnatomy, Physiology, and Embryology of the Pancreas
El‐Gohary, Y., & Gittes, G. K. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2206-2.00087-7 · Cited by 1
Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice
Åhrén, B. (2021) · Peptides · doi:10.1016/j.peptides.2021.170650 · Cited by 2
Ogawa, Y., Kimura, H., Fujimoto, H., Kawashima, H., Toyoda, K., Mukai, E., Yagi, Y., Ono, M., Inagaki, N., & Saji, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116496 · Cited by 1
Hypothalamic neural networks in control of glucose homeostasis
Yi, C. (2010) · UvA-DARE (University of Amsterdam) · Cited by 1
Glucagon-like peptide-1 (GLP-1) and satiation
Rüttimann, E. B. (2010) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-006089995 · Cited by 3
Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Rayas, M. S., Gastaldelli, A., Honka, H., Pezzica, S., Carli, F., Peterson, R. E., DeFronzo, R. A., & Salehi, M. (2023) · medRxiv · doi:10.1101/2023.10.22.23297377 · Cited by 1
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Ferreira, M. C. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-01112013-113904 · Cited by 3
The role of short chain fatty acids in appetite regulation
Psichas, A. (2013) · doi:10.25560/23364 · Cited by 1
Mithieux, G. (2013) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2013.02.002
POUR LE DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE
Sabatier, P., Médecine, F. D., Clinique, M. S., & Bally, É. (2013)
The Role of Incretins in Insulin Secretion
Salehi, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_4-1
Wilson, H. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Glucose Metabolism in the Intestine
Ha, E. (2016) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2016.5.1.1
“Ghrelin, CCK, PYY, GLP-1에 의한 효과는 vagotomy에 의해 감소된다는 연구 결과 보고를 통해 장호르몬 작용에는 위장 관 신경도 관련되어 있다는 것이 밝혀졌다[3-6].”
Metadata
- Authors
- Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., & D’Alessio, D. A.
- Affiliations
- University of Cincinnati (US)
- Corresponding author
- D’Alessio, David A.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 148
- Issue
- 10
- Pages
- 4965-4973
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2128181185
- Cited by
- 318
- References
- 57
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 9 · 2021: 20 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 14 · 2016: 21 · 2015: 25 · 2014: 24 · 2013: 32 · 2012: 23
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Cincinnati
- National Institutes of Health (DK17844)
- National Institute of Mental Health (MH 069680)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 54263, DK17844, R01DK054890, DK-54890, T35DK060444)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, glucose tolerance, portal vein, visceral afferent neurons, nodose ganglion, exendin-4, glucose homeostasis, intraportal infusion
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Dose-Response Relationship, Drug, Glucose, Glucose Tolerance Test, Infusions, Intravenous, Liver, Male, Nerve Endings, Nodose Ganglion, Peptides, Portal Vein, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Glucose Intolerance, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.